Physician profile
Barbara E Stancil
NPI 1679665418
$5,151.20
in general payments reported to CMS, 2019-2025
11 companies · $536 in 2025
The $536 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $873 · 2023: $2,185 · 2024: $1,558 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,416 · Travel and Lodging: $1,562 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,416.23 |
| Travel and Lodging | $1,562.43 |
| Education | $299.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $3,584.30 | 2022-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $743.29 | 2022-2024 | |
| Harmony Biosciences LLC | $599.50 | 2022-2025 | Wakix |
| Axsome Therapeutics, INC. | $84.04 | 2024-2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $29.82 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $24.11 | 2024 | Lumryz |
| United Therapeutics Corporation | $21.80 | 2022 | |
| Phadia US INC. | $17.92 | 2023 | Immunocap |
| Glaxosmithkline, LLC. | $17.70 | 2025 | Nucala |
| Alexion Pharmaceuticals, INC. | $16.98 | 2023 | Ultomiris |
| Mylan Specialty L.P. | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Stancil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.